Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Asenapine (1) ·
Butorphanol (1) ·
Chlorpromazine (1) ·
Codeine (2) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Droperidol (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Fluphenazine (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Iloperidone (1) ·
Levorphanol (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Meperidine (1) ·
Molindone (1) ·
Nalbuphine (1) ·
Olanzapine / Fluoxetine (1) ·
Oxymorphone (1) ·
Paliperidone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Perphenazine (1) ·
Pimozide (1) ·
Tapentadol (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Trifluoperazine (1) ·
Valproate (valproic acid, divalproex sodium, sodium valproate) (1) ·
Ziprasidone (1)
brand:
None (5) ·
(multiple, generic dominant) (1) ·
Darvon (1) ·
Demerol (1) ·
Depakote, Depakote ER, Depakene, Depacon (IV) (1) ·
Dilaudid (1) ·
Duragesic (1) ·
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Orap (1) ·
Prolixin (1) ·
Saphris (1) ·
Stadol (1) ·
Stelazine (1) ·
Symbyax (1) ·
Talwin (1) ·
Thorazine (1) ·
Trilafon (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Thioxanthene D2 antagonist (1) ·
'"`UNIQ--vote-00000975-QINU`"' Hyperammonemic encephalopathy (consider in any unexplained CNS depression), thrombocytopenia, and polycystic ovary syndrome are characteristic chronic-use adverse effects beyond hepatic and pancreatic risks'"`UNIQ--ref-00000976-QINU`"'. (1) ·
'"`UNIQ--vote-00001549-QINU`"' Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard'"`UNIQ--ref-0000154A-QINU`"'. (1)
uses:
None (30) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-00000977-QINU`"', '"`UNIQ--vote-00000978-QINU`"', '"`UNIQ--vote-00000979-QINU`"', '"`UNIQ--vote-0000097A-QINU`"', '"`UNIQ--vote-0000097B-QINU`"' (1) ·
'"`UNIQ--vote-0000154B-QINU`"', '"`UNIQ--vote-0000154C-QINU`"' (1)
starting dose:
None (30) ·
6/25 mg PO once daily in the evening; titrate within range 3/25 to 18/75 mg by clinical response and tolerability (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Seizures: 10-15 mg/kg/d divided BID-TID, titrate to therapeutic level (50-100 mcg/mL); bipolar mania: 750 mg/d divided, titrate (1)
preparations:
None (30) ·
125, 250, 500 mg delayed-release tablets (Depakote); 250, 500 mg ER tablets (Depakote ER); 125, 250 mg sprinkle capsules; 250 mg/5 mL syrup; 500 mg IV (Depacon) (1) ·
Capsules: 3/25, 6/25, 6/50, 12/25, 12/50 mg olanzapine/fluoxetine (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (30) ·
Olanzapine 60% (oral); fluoxetine high (oral)'"`UNIQ--ref-0000154E-QINU`"' (1) ·
~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)'"`UNIQ--ref-0000097D-QINU`"' (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (30) ·
'''Contraindicated for migraine prophylaxis in pregnancy; high teratogenic risk''' (neural tube defects, craniofacial anomalies, cardiac defects, cognitive/IQ impairment); avoid in women of childbearing potential without reliable contraception when alternatives exist'"`UNIQ--ref-0000097E-QINU`"' (1) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (30) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for hepatotoxicity (especially children <2 with metabolic disorders), teratogenicity, and pancreatitis'"`UNIQ--ref-0000097F-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients'"`UNIQ--ref-0000154F-QINU`"' (1)
Showing below up to 33 results in range #1 to #33.